Avenue Therapeutics, Inc. Annual report pursuant to Section 13 and 15(d)

Note 4 - Related Party Agreements (Details Textual) - USD ($) $ in Thousands				1 Months Ended	12 Months Ended
	Mar. 09, 2017	Sep. 13, 2016	Feb. 17, 2015	Feb. 28, 2015	Dec. 31, 2023	Dec. 31, 2022	Nov. 08, 2022
Fortress [Member]
Notes Assumed				$ 3,000
Percentage of Fully-diluted Outstanding Equity				2.50%
Percentage of Equity or Debt Fnancing				2.50%
Percentage of Annual net Sales				4.50%
Amended Founders Agreements Terms (Year)		15 years
Number Of Shares Exchanged (in shares)		166,027
Fortress [Member] \| Management Services Agreement [Member]
Term of Agreement (Year)			5 years
Automatic Renewal Term of Agreement (Year)			5 years
Annual Consulting Fee			$ 500
Increase in Annual Consulting Fee			1,000
Excess in Net Assets Value			$ 100,000
Fortress [Member] \| Avenue Baergic Founders Agreement [Member]
Excess in Net Assets Value	$ 100,000
Fortress [Member] \| Common Class A [Member]
Number Of Shares Exchanged (in shares)		155,555
Fortress [Member] \| Preferred Class A [Member]
Number Of Shares Exchanged (in shares)		250,000
BaergicBio, Inc.[Member]
Proceeds From Equity Fee					$ 23	$ 10
BaergicBio, Inc.[Member] \| Founders Agreement and Management Services Agreement [Member]
Percentage of Equity Fee							2.50%
BaergicBio, Inc.[Member] \| Avenue Baergic Founders Agreement [Member]
Term of Agreement (Year)	5 years
Annual Consulting Fee	$ 500
Increase in Annual Consulting Fee	$ 1,000
Percentage Of Additional Consideration Of Equity Fee						2.50%
Percentage Considered For The Calculation Of One-Time Fee						4.50%